Analyst Ratings For Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Today, B. Riley raised its price target on Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $4.00 per share.
Some recent analyst ratings include
- 1/16/2018-Chardan Capital Reiterated Rating of Neutral.
- 11/27/2017-Piper Jaffray Companies Upgrade from a “Neutral ” rating to a ” Overweight” rating.
- 9/18/2017-William Blair Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
- 8/4/2017-Jefferies Group Reiterated Rating of Hold.
Recent Insider Trading Activity For Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals (NASDAQ:ARWR) has insider ownership of 4.60% and institutional ownership of 20.48%.
- On 1/1/2018 Bruce D Given, COO, sold 20,000 with an average share price of $3.69 per share and the total transaction amounting to $73,800.00.
- On 10/14/2016 Douglas B. Given, Director, sold 12,000 with an average share price of $6.72 per share and the total transaction amounting to $80,640.00.
- On 8/23/2016 Kenneth Allen Myszkowski, CFO, sold 6,900 with an average share price of $8.00 per share and the total transaction amounting to $55,200.00.
- On 8/22/2016 Kenneth Allen Myszkowski, CFO, sold 13,100 with an average share price of $8.00 per share and the total transaction amounting to $104,800.00.
- On 12/30/2015 Kenneth Allen Myszkowski, CFO, sold 23,347 with an average share price of $6.13 per share and the total transaction amounting to $143,117.11.
- On 10/28/2015 Mauro Ferrari, Director, bought 400 with an average share price of $7.62 per share and the total transaction amounting to $3,048.00.
- On 10/9/2015 Mauro Ferrari, Director, bought 1,900 with an average share price of $6.19 per share and the total transaction amounting to $11,761.00.
Recent Trading Activity for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Shares of Arrowhead Pharmaceuticals closed the previous trading session at 5.53 down -0.06 1.07% with 5.329999923706055 shares trading hands.